MedTrace Logo

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 261

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).

Conditions

Interventions

COMBINATION_PRODUCT

ALXN1720

Combination product consisting of syringe prefilled with ALXN1720.

COMBINATION_PRODUCT

Placebo

Combination product consisting of syringe prefilled with placebo.

Sponsors & Collaborators

  • Alexion Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-21
Primary Completion
2025-05-27
Completion
2027-08-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Argentina
  • Austria
  • Brazil
  • Canada
  • China
  • Denmark
  • France
  • Germany
  • Israel
  • Italy
  • Japan
  • Netherlands
  • Poland
  • Portugal
  • Serbia
  • South Korea
  • Spain
  • Switzerland
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05556096 on ClinicalTrials.gov